河南汉族CYP2C19基因多态性对氯吡格雷药物代谢动力学的影响
Effect of CYP2C19 genetic polymorphism on pharmacokinetics of clopidogrel

目的：探讨CYP2C19基因多态性对氯吡格雷人体药物代谢动力学的影响。方法：43名健康受试者在单次服用75 mg氯吡格雷片后，定时采血，用液质联用技术（LC？？MS/MS）分析受试者氯吡格雷血药浓度，采用PCR？蚕拗菩云？段长度多态性分析法检测CYP2C19*2、*3基因突变。结果：CYP2C19*1/*1、CYP2C19*1/*2和CYP2C19*2/*2(*3)3种基因型分别为13、24和6例。药时曲线下面积（AUC）0？？24和AUC0？病拊谌？种基因型间比较，差异有统计学意义（P<0.05）。结论：口服氯吡格雷后，CYP2C19不同基因型AUC不同。
Aim: To determine the effect of CYP2C19 genetic polymorphism on the pharmacokinetics of clopidogrel in healthy Chinese subjects.Methods: A total of 43 unrelated healthy Han subjects were enrolled, and each of them received a single dose of 75 mg clopidogrel tablet. Multiple blood samples were collected and the plasma concentrations of clopidogrel were determined by a validated liquid chromatography/tandem mass spectrometry. PCR？？restriction fragment length polymorphism analysis was performed to detect the CYP2C19*2 and *3 gene mutations.Results: The number of the inviduals carrying CYP2C19*1/*1, CYP2C19*1/*2 and CYP2C19*2/*2 (*3) were 13, 24 and 6, respectively. There were significant differences in the various genotype groups of AUC0？？24 and AUC0？病？(P<0.05).Conclusion: CYP2C19 polymorphisms affect the AUC of clopidogrel